Hannah Joseph Hospital is evolving from a regional neurosciences and trauma centre into a scalable specialized healthcare platform focused on high-acuity care. With a strong presence in neurosciences, critical care, and trauma, the company is now entering its next growth phase through an IPO-funded oncology expansion.
Key highlights:
* Revenue grew to ₹92 crore in FY26, with EBITDA margins of 27.4%
* Oncology division funded through ~₹35 crore IPO proceeds, expected to enhance patient retention and revenue visibility
* Plans to replicate its specialized care model through 80–100 bed hubs across key South Indian cities
* Strong positioning in high-complexity neuro and trauma care, supported by advanced technology and clinical expertise
ValPro initiates coverage with a *BUY* rating, assigning a *Target Price of ₹200* over a 24-month horizon.
Read the full report for our detailed investment thesis.
#Healthcare #Hospitals #SMEStocks #HealthcareServices #Oncology #Neurosciences #ValPro
